Memantine transport by a proton-coupled organic cation antiporter in hCMEC/D3 cells, an in vitro human blood-brain barrier model

Memantine is clinically used for the treatment of patients with Alzheimer's disease and is highly distributed to the brain. The aim of this study is to characterize memantine transport at the blood–brain barrier (BBB) using hCMEC/D3 cells, a human BBB model. The initial uptake velocity of meman...

Full description

Saved in:
Bibliographic Details
Published inDrug metabolism and pharmacokinetics Vol. 30; no. 2; pp. 182 - 187
Main Authors Higuchi, Kei, Kitamura, Atsushi, Okura, Takashi, Deguchi, Yoshiharu
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.04.2015
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Memantine is clinically used for the treatment of patients with Alzheimer's disease and is highly distributed to the brain. The aim of this study is to characterize memantine transport at the blood–brain barrier (BBB) using hCMEC/D3 cells, a human BBB model. The initial uptake velocity of memantine in hCMEC/D3 cells was concentration-dependent, and was reduced by metabolic inhibitors, but was independent of extracellular sodium ion and membrane potential. Intracellular alkalization and intracellular acidification markedly reduced and enhanced the uptake, respectively. The uptake was strongly inhibited by quinidine, pyrilamine and verapamil, and was moderately inhibited by TEA (substrate of OCTs and OCTNs) and l-carnitine (substrate of OCTN2), but was not inhibited by MPP+ (substrate of OCTs and PMAT) or ergothioneine (substrate of OCTN1). Although relatively abundant expression of OCTN2 gene has been observed in hCMEC/D3 cells, knockdown of OCTN2 with siRNA did not decrease memantine uptake. Memantine and diphenhydramine each showed inhibition of the other's uptake in a competitive manner. Thus, proton-coupled organic cation antiporter(s) appears to be involved in the transport of memantine in hCMEC/D3 cells, at least in part. Our results indicate that the in vivo BBB permeability of memantine in humans can be predicted from the in vitro uptake clearance in hCMEC/D3 cells.
AbstractList Memantine is clinically used for the treatment of patients with Alzheimer's disease and is highly distributed to the brain. The aim of this study is to characterize memantine transport at the blood-brain barrier (BBB) using hCMEC/D3 cells, a human BBB model. The initial uptake velocity of memantine in hCMEC/D3 cells was concentration-dependent, and was reduced by metabolic inhibitors, but was independent of extracellular sodium ion and membrane potential. Intracellular alkalization and intracellular acidification markedly reduced and enhanced the uptake, respectively. The uptake was strongly inhibited by quinidine, pyrilamine and verapamil, and was moderately inhibited by TEA (substrate of OCTs and OCTNs) and l-carnitine (substrate of OCTN2), but was not inhibited by MPP(+) (substrate of OCTs and PMAT) or ergothioneine (substrate of OCTN1). Although relatively abundant expression of OCTN2 gene has been observed in hCMEC/D3 cells, knockdown of OCTN2 with siRNA did not decrease memantine uptake. Memantine and diphenhydramine each showed inhibition of the other's uptake in a competitive manner. Thus, proton-coupled organic cation antiporter(s) appears to be involved in the transport of memantine in hCMEC/D3 cells, at least in part. Our results indicate that the in vivo BBB permeability of memantine in humans can be predicted from the in vitro uptake clearance in hCMEC/D3 cells.Memantine is clinically used for the treatment of patients with Alzheimer's disease and is highly distributed to the brain. The aim of this study is to characterize memantine transport at the blood-brain barrier (BBB) using hCMEC/D3 cells, a human BBB model. The initial uptake velocity of memantine in hCMEC/D3 cells was concentration-dependent, and was reduced by metabolic inhibitors, but was independent of extracellular sodium ion and membrane potential. Intracellular alkalization and intracellular acidification markedly reduced and enhanced the uptake, respectively. The uptake was strongly inhibited by quinidine, pyrilamine and verapamil, and was moderately inhibited by TEA (substrate of OCTs and OCTNs) and l-carnitine (substrate of OCTN2), but was not inhibited by MPP(+) (substrate of OCTs and PMAT) or ergothioneine (substrate of OCTN1). Although relatively abundant expression of OCTN2 gene has been observed in hCMEC/D3 cells, knockdown of OCTN2 with siRNA did not decrease memantine uptake. Memantine and diphenhydramine each showed inhibition of the other's uptake in a competitive manner. Thus, proton-coupled organic cation antiporter(s) appears to be involved in the transport of memantine in hCMEC/D3 cells, at least in part. Our results indicate that the in vivo BBB permeability of memantine in humans can be predicted from the in vitro uptake clearance in hCMEC/D3 cells.
Memantine is clinically used for the treatment of patients with Alzheimer's disease and is highly distributed to the brain. The aim of this study is to characterize memantine transport at the blood-brain barrier (BBB) using hCMEC/D3 cells, a human BBB model. The initial uptake velocity of memantine in hCMEC/D3 cells was concentration-dependent, and was reduced by metabolic inhibitors, but was independent of extracellular sodium ion and membrane potential. Intracellular alkalization and intracellular acidification markedly reduced and enhanced the uptake, respectively. The uptake was strongly inhibited by quinidine, pyrilamine and verapamil, and was moderately inhibited by TEA (substrate of OCTs and OCTNs) and l-carnitine (substrate of OCTN2), but was not inhibited by MPP(+) (substrate of OCTs and PMAT) or ergothioneine (substrate of OCTN1). Although relatively abundant expression of OCTN2 gene has been observed in hCMEC/D3 cells, knockdown of OCTN2 with siRNA did not decrease memantine uptake. Memantine and diphenhydramine each showed inhibition of the other's uptake in a competitive manner. Thus, proton-coupled organic cation antiporter(s) appears to be involved in the transport of memantine in hCMEC/D3 cells, at least in part. Our results indicate that the in vivo BBB permeability of memantine in humans can be predicted from the in vitro uptake clearance in hCMEC/D3 cells.
Memantine is clinically used for the treatment of patients with Alzheimer's disease and is highly distributed to the brain. The aim of this study is to characterize memantine transport at the blood–brain barrier (BBB) using hCMEC/D3 cells, a human BBB model. The initial uptake velocity of memantine in hCMEC/D3 cells was concentration-dependent, and was reduced by metabolic inhibitors, but was independent of extracellular sodium ion and membrane potential. Intracellular alkalization and intracellular acidification markedly reduced and enhanced the uptake, respectively. The uptake was strongly inhibited by quinidine, pyrilamine and verapamil, and was moderately inhibited by TEA (substrate of OCTs and OCTNs) and l-carnitine (substrate of OCTN2), but was not inhibited by MPP+ (substrate of OCTs and PMAT) or ergothioneine (substrate of OCTN1). Although relatively abundant expression of OCTN2 gene has been observed in hCMEC/D3 cells, knockdown of OCTN2 with siRNA did not decrease memantine uptake. Memantine and diphenhydramine each showed inhibition of the other's uptake in a competitive manner. Thus, proton-coupled organic cation antiporter(s) appears to be involved in the transport of memantine in hCMEC/D3 cells, at least in part. Our results indicate that the in vivo BBB permeability of memantine in humans can be predicted from the in vitro uptake clearance in hCMEC/D3 cells.
Author Okura, Takashi
Higuchi, Kei
Deguchi, Yoshiharu
Kitamura, Atsushi
Author_xml – sequence: 1
  givenname: Kei
  surname: Higuchi
  fullname: Higuchi, Kei
– sequence: 2
  givenname: Atsushi
  surname: Kitamura
  fullname: Kitamura, Atsushi
– sequence: 3
  givenname: Takashi
  surname: Okura
  fullname: Okura, Takashi
– sequence: 4
  givenname: Yoshiharu
  surname: Deguchi
  fullname: Deguchi, Yoshiharu
  email: deguchi@pharm.teikyo-u.ac.jp
BackLink https://www.ncbi.nlm.nih.gov/pubmed/25857234$$D View this record in MEDLINE/PubMed
BookMark eNp9kbtu1jAYhi1URA9wAwzIIwNJfUjiRGJBP4UitWKA3fLhC_VPYgfbqdSRO-FauDKc_u3C0MmW_Tw-vO8pOvLBA0KvKakpod35vrbz8rNmhDY1ZTUh3TN0QvueVGRg5KjMeSOqhnfiGJ2mtCeE87ZhL9Axa_tWMN6coN_XMCufnQeco_JpCTFjfYcVXmLIwVcmrMsEFof4Q3lnsFHZBY83Z2MhYufxze76Ynf-kWMD05Teld2y-vfPrcsx4Ju13ID1FIKtdFQF1ypGV8w5WJheouejmhK8ehjP0LdPF993l9XV189fdh-uKtMMJFfcCjDCCE5HPYDQrWKdtWbQYyvallk6Es2YHlrFez1yRhuqmGisYo3mwM_Q28Op5Vu_VkhZzi5tr1Uewpok7QTryNDTtqBvHtBVz2DlEt2s4p18DK0A_QEwMaQUYZTG5ftYSoRukpTIrR-5l1s_cutHUiZLP0Vl_6mPpz8pvT9IUOK5LcHJZBx4A9ZFMFna4J7S_wEye6tr
CitedBy_id crossref_primary_10_1039_C6MD00509H
crossref_primary_10_1016_j_jep_2020_112581
crossref_primary_10_1016_j_xphs_2018_11_040
crossref_primary_10_3390_pharmaceutics14081683
crossref_primary_10_2217_nnm_2017_0023
crossref_primary_10_1016_j_xphs_2017_04_032
crossref_primary_10_1007_s11095_023_03583_0
crossref_primary_10_1021_acsmedchemlett_8b00099
crossref_primary_10_1111_bcpt_14090
crossref_primary_10_1186_s12987_024_00544_6
crossref_primary_10_1016_j_jconrel_2022_08_051
crossref_primary_10_1021_acs_molpharmaceut_9b00042
crossref_primary_10_1248_bpb_b22_00347
crossref_primary_10_1371_journal_pone_0128890
crossref_primary_10_1016_j_jconrel_2017_03_034
crossref_primary_10_1021_acs_molpharmaceut_6b00818
crossref_primary_10_1002_prp2_879
crossref_primary_10_1177_1179573517693802
crossref_primary_10_4062_biomolther_2019_007
crossref_primary_10_1007_s11095_022_03281_3
crossref_primary_10_1016_j_neuropharm_2017_08_002
crossref_primary_10_1021_acs_molpharmaceut_8b00617
crossref_primary_10_1016_j_bbih_2020_100188
crossref_primary_10_1016_j_pharmthera_2022_108283
crossref_primary_10_3390_futurepharmacol3040046
crossref_primary_10_1016_j_ajps_2015_11_010
crossref_primary_10_1002_jps_24691
crossref_primary_10_1002_bdd_2014
crossref_primary_10_1016_j_expneurol_2022_114181
crossref_primary_10_1016_j_brainres_2021_147581
crossref_primary_10_1124_dmd_120_000115
crossref_primary_10_3390_pharmaceutics12020154
crossref_primary_10_3390_pharmaceutics16030330
crossref_primary_10_1016_j_pnpbp_2021_110409
crossref_primary_10_1248_bpb_b24_00329
crossref_primary_10_1007_s11095_022_03223_z
crossref_primary_10_1021_acs_molpharmaceut_0c01104
crossref_primary_10_1016_j_xphs_2020_09_001
crossref_primary_10_3389_fncel_2024_1493644
Cites_doi 10.1016/j.phrs.2004.05.005
10.1007/s11095-012-0926-y
10.1096/fj.04-3458fje
10.1111/j.1471-4159.2011.07208.x
10.1016/j.neuint.2012.11.014
10.1002/jps.24129
10.1111/j.1600-0773.1993.tb01564.x
10.1021/mp900178j
10.1124/dmd.108.022087
10.1186/2045-8118-10-8
10.1016/j.bbamem.2007.08.023
10.1016/0922-4106(91)90113-V
10.1023/A:1018856020583
10.1124/dmd.106.010876
10.1021/mp400316e
10.1038/jcbfm.2009.54
10.1021/mp300570z
10.1254/jphs.12043FP
10.1007/s007020050073
10.2133/dmpk.DMPK-13-RG-058
10.1345/aph.1K619
10.1016/S0028-3908(99)00019-2
10.1002/jps.23535
10.1016/S0969-8051(01)00293-1
10.1002/jps.22567
10.1007/s10334-003-0004-x
10.1371/currents.RRN1291
10.1021/mp3004308
10.1016/j.lfs.2007.01.035
10.1124/mol.54.2.342
10.1002/gps.938
ContentType Journal Article
Copyright 2014 The Japanese Society for the Study of Xenobiotics
Copyright © 2014 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.
Copyright_xml – notice: 2014 The Japanese Society for the Study of Xenobiotics
– notice: Copyright © 2014 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1016/j.dmpk.2014.12.006
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1880-0920
EndPage 187
ExternalDocumentID 25857234
10_1016_j_dmpk_2014_12_006
S1347436714000275
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
--M
0R~
29G
2WC
4.4
457
53G
5GY
7-5
8P~
AACTN
AAEDT
AAEDW
AAIAV
AAIKJ
AAKOC
AALRI
AAOAW
AATCM
AAXUO
ABJNI
ABMAC
ABXDB
ABYKQ
ACDAQ
ACGFO
ACGFS
ACRLP
ADBBV
ADEZE
AEBSH
AEKER
AENEX
AFKWA
AFTJW
AFXIZ
AGHFR
AGUBO
AIEXJ
AIKHN
AITUG
AJBFU
AJOXV
ALMA_UNASSIGNED_HOLDINGS
AMFUW
AMRAJ
AXJTR
BAWUL
BKOJK
BKOMP
BLXMC
CS3
DIK
DU5
E3Z
EBS
EFJIC
EFLBG
EJD
F5P
FDB
FEDTE
FIRID
FYGXN
GBLVA
GX1
HH5
HVGLF
HZ~
JMI
JSF
JSH
KOM
KQ8
M41
MOJWN
M~E
O9-
OAUVE
RJT
RNS
ROL
RZJ
SPCBC
SSP
SSZ
T5K
TKC
TR2
~G-
AAQFI
AATTM
AAXKI
AAYWO
AAYXX
ACVFH
ADCNI
AEIPS
AEUPX
AFJKZ
AFPUW
AGCQF
AGRNS
AIGII
AIIUN
AKBMS
AKRWK
AKYEP
ANKPU
APXCP
BNPGV
CITATION
OVT
SSH
CGR
CUY
CVF
ECM
EFKBS
EIF
NPM
7X8
ID FETCH-LOGICAL-c490t-3d7ec7c731fb9e7b5a26ddc9bf57552d1f0b22b95a38bf32141a274da24b3e3
IEDL.DBID AIKHN
ISSN 1347-4367
1880-0920
IngestDate Mon Jul 21 11:24:54 EDT 2025
Mon Jul 21 06:02:08 EDT 2025
Tue Jul 01 03:08:23 EDT 2025
Thu Apr 24 23:05:22 EDT 2025
Fri Feb 23 02:32:23 EST 2024
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords Proton-coupled organic cation antiporter
Active transport
Memantine
hCMEC/D3 cells
Blood–brain barrier
Language English
License https://www.elsevier.com/tdm/userlicense/1.0
Copyright © 2014 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c490t-3d7ec7c731fb9e7b5a26ddc9bf57552d1f0b22b95a38bf32141a274da24b3e3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 25857234
PQID 1672609815
PQPubID 23479
PageCount 6
ParticipantIDs proquest_miscellaneous_1672609815
pubmed_primary_25857234
crossref_citationtrail_10_1016_j_dmpk_2014_12_006
crossref_primary_10_1016_j_dmpk_2014_12_006
elsevier_sciencedirect_doi_10_1016_j_dmpk_2014_12_006
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2015-04-01
PublicationDateYYYYMMDD 2015-04-01
PublicationDate_xml – month: 04
  year: 2015
  text: 2015-04-01
  day: 01
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Drug metabolism and pharmacokinetics
PublicationTitleAlternate Drug Metab Pharmacokinet
PublicationYear 2015
Publisher Elsevier Ltd
Publisher_xml – name: Elsevier Ltd
References Deo, Theil, Nicolas (bib27) 2013; 10
Hesselink, De Boer, Breimer, Danysz (bib31) 1999; 16
Weksler, Subileau, Perriere, Charneau, Holloway, Leveque (bib12) 2005; 19
Shimomura, Okura, Kato, Couraud, Scherrmann, Terasaki (bib16) 2013; 10
Okura, Kato, Deguchi (bib15) 2014; 29
Kuwayama, Inoue, Kanamori, Tsujikawa, Miyaguchi, Iwata (bib20) 2008; 1778
Beconi, Howland, Park, Lyons, Giuliano, Dominguez (bib4) 2011; 3
Okura, Hattori, Takano, Sato, Hammarlund-Udenaes, Terasaki (bib9) 2008; 36
Uchida, Ohtsuki, Katsukura, Ikeda, Suzuki, Kamiie (bib11) 2011; 117
Lin, Shic, Enriquez, Ross (bib2) 2003; 16
Ohtsuki, Ikeda, Uchida, Sakamoto, Miller, Glacial (bib14) 2013; 7
Mehta, Short, Nicolazzo (bib8) 2013; 10
Parsons, Danysz, Quack (bib29) 1999; 38
Danysz, Parsons (bib3) 2003; 18
Ohta, Inoue, Hayashi, Yuasa (bib18) 2006; 34
Honegger, Quack, Wiesmann (bib19) 1993; 73
Moellentin, Picone, Leadbetter (bib6) 2008; 42
Smith (bib26) 2003; 89
Moritoyo, Hasunuma, Harada, Tateishi, Watanabe, Kotegawa (bib28) 2012; 119
Ametamey, Bruehlmeier, Kneifel, Kokic, Honer, Arigoni (bib7) 2002; 29
Kubo, Shimizu, Kusagawa, Akanuma, Hosoya (bib24) 2013; 102
Kubo, Kusagawa, Tachikawa, Akanuma, Hosoya (bib25) 2013; 30
Kornhuber, Bormann, Hübers, Rusche, Riederer (bib32) 1991; 206
Busch, Karbach, Miska, Gorboulev, Akhoundova, Volk (bib5) 1998; 54
Kitamura, Higuchi, Okura, Deguchi (bib17) 2014; 103
Tega, Akanuma, Kubo, Terasaki, Hosoya (bib22) 2013; 62
Jimenez-Jimenez, Molina, Gomez, Vargas, De Bustos, Benito-Leon (bib1) 1998; 105
André, Debray, Scherrmann, Cisternino (bib21) 2009; 29
Okura, Ito, Ishiguro, Tamai, Deguchi (bib23) 2007; 80
Sadiq, Borgs, Okura, Shimomura, Kato, Deguchi (bib10) 2011; 100
Carl, Lindley, Das, Couraud, Weksler, Romero (bib13) 2010; 2
Sonkusare, Kaul, Ramarao (bib30) 2005; 51
Okura (10.1016/j.dmpk.2014.12.006_bib9) 2008; 36
Okura (10.1016/j.dmpk.2014.12.006_bib15) 2014; 29
Parsons (10.1016/j.dmpk.2014.12.006_bib29) 1999; 38
Carl (10.1016/j.dmpk.2014.12.006_bib13) 2010; 2
Kornhuber (10.1016/j.dmpk.2014.12.006_bib32) 1991; 206
Ametamey (10.1016/j.dmpk.2014.12.006_bib7) 2002; 29
Sonkusare (10.1016/j.dmpk.2014.12.006_bib30) 2005; 51
Mehta (10.1016/j.dmpk.2014.12.006_bib8) 2013; 10
Kitamura (10.1016/j.dmpk.2014.12.006_bib17) 2014; 103
Lin (10.1016/j.dmpk.2014.12.006_bib2) 2003; 16
Sadiq (10.1016/j.dmpk.2014.12.006_bib10) 2011; 100
Ohta (10.1016/j.dmpk.2014.12.006_bib18) 2006; 34
Danysz (10.1016/j.dmpk.2014.12.006_bib3) 2003; 18
Weksler (10.1016/j.dmpk.2014.12.006_bib12) 2005; 19
Shimomura (10.1016/j.dmpk.2014.12.006_bib16) 2013; 10
Kubo (10.1016/j.dmpk.2014.12.006_bib25) 2013; 30
André (10.1016/j.dmpk.2014.12.006_bib21) 2009; 29
Tega (10.1016/j.dmpk.2014.12.006_bib22) 2013; 62
Beconi (10.1016/j.dmpk.2014.12.006_bib4) 2011; 3
Busch (10.1016/j.dmpk.2014.12.006_bib5) 1998; 54
Moritoyo (10.1016/j.dmpk.2014.12.006_bib28) 2012; 119
Uchida (10.1016/j.dmpk.2014.12.006_bib11) 2011; 117
Smith (10.1016/j.dmpk.2014.12.006_bib26) 2003; 89
Honegger (10.1016/j.dmpk.2014.12.006_bib19) 1993; 73
Deo (10.1016/j.dmpk.2014.12.006_bib27) 2013; 10
Kuwayama (10.1016/j.dmpk.2014.12.006_bib20) 2008; 1778
Okura (10.1016/j.dmpk.2014.12.006_bib23) 2007; 80
Moellentin (10.1016/j.dmpk.2014.12.006_bib6) 2008; 42
Ohtsuki (10.1016/j.dmpk.2014.12.006_bib14) 2013; 7
Hesselink (10.1016/j.dmpk.2014.12.006_bib31) 1999; 16
Kubo (10.1016/j.dmpk.2014.12.006_bib24) 2013; 102
Jimenez-Jimenez (10.1016/j.dmpk.2014.12.006_bib1) 1998; 105
References_xml – volume: 29
  start-page: 69
  year: 2014
  end-page: 74
  ident: bib15
  article-title: Functional expression of organic cation/carnitine transporter 2 (OCTN2/SLC22A5) in human brain capillary endothelial cell line hCMEC/D3, a human blood-brain barrier model
  publication-title: Drug Metab Pharmacokinet
– volume: 42
  start-page: 443
  year: 2008
  end-page: 447
  ident: bib6
  article-title: Memantine-induced myoclonus and delirium exacerbated by trimethoprim
  publication-title: Ann Pharmacother
– volume: 119
  start-page: 324
  year: 2012
  end-page: 329
  ident: bib28
  article-title: Effect of renal impairment on the pharmacokinetics of memantine
  publication-title: J Pharm Sci
– volume: 105
  start-page: 269
  year: 1998
  end-page: 277
  ident: bib1
  article-title: Neurotransmitter amino acids in cerebrospinal fluid of patients with Alzheimer's disease
  publication-title: J Neural Transm
– volume: 10
  start-page: 8
  year: 2013
  ident: bib16
  article-title: Functional expression of a proton-coupled organic cation (H
  publication-title: Fluids Barriers CNS
– volume: 1778
  start-page: 42
  year: 2008
  end-page: 50
  ident: bib20
  article-title: Uptake of 3, 4-methylenedioxymethamphetamine and its related compounds by a proton-coupled transport system in Caco-2 cells
  publication-title: Biochim Biophys Acta
– volume: 10
  start-page: 1581
  year: 2013
  end-page: 1595
  ident: bib27
  article-title: Confounding parameters in preclinical assessment of blood–brain barrier permeation: an overview with emphasis on species differences and effect of disease states
  publication-title: Mol Pharm
– volume: 16
  start-page: 637
  year: 1999
  end-page: 642
  ident: bib31
  article-title: Brain penetration and in vivo recovery of NMDA receptor antagonists amantadine and memantine: a quantitative microdialysis study
  publication-title: Pharm Res
– volume: 10
  start-page: 4491
  year: 2013
  end-page: 4498
  ident: bib8
  article-title: Memantine transport across the mouse blood–brain barrier is mediated by a cationic influx H
  publication-title: Mol Pharm
– volume: 100
  start-page: 3912
  year: 2011
  end-page: 3923
  ident: bib10
  article-title: Diphenhydramine active uptake at the blood–brain barrier and its interaction with oxycodone in vitro and in vivo
  publication-title: J Pharm Sci
– volume: 34
  start-page: 1868
  year: 2006
  end-page: 1874
  ident: bib18
  article-title: Molecular identification and functional characterization of rat multidrug and toxin extrusion type transporter 1 as an organic cation/H
  publication-title: Drug Metab Dispos
– volume: 206
  start-page: 297
  year: 1991
  end-page: 300
  ident: bib32
  article-title: Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study
  publication-title: Eur J Pharmacol
– volume: 36
  start-page: 2005
  year: 2008
  end-page: 2013
  ident: bib9
  article-title: Involvement of the pyrilamine transporter, a putative organic cation transporter, in blood-brain barrier transport of oxycodone
  publication-title: Drug Metab Dispos
– volume: 80
  start-page: 1564
  year: 2007
  end-page: 1571
  ident: bib23
  article-title: Blood–brain barrier transport of pramipexole, a dopamine D2 agonist
  publication-title: Life Sci
– volume: 30
  start-page: 847
  year: 2013
  end-page: 856
  ident: bib25
  article-title: Involvement of a novel organic cation transporter in verapamil transport across the inner blood-retinal barrier
  publication-title: Pharm Res
– volume: 18
  start-page: S23
  year: 2003
  end-page: S32
  ident: bib3
  article-title: The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence
  publication-title: Int J Geriatr Psychiatry
– volume: 2
  start-page: 1057
  year: 2010
  end-page: 1068
  ident: bib13
  article-title: ABC and SLC transporter expression and proton oligopeptide transporter (POT) mediated permeation across the human blood–brain barrier cell line, hCMEC/D3
  publication-title: Mol Pharm
– volume: 73
  start-page: 202
  year: 1993
  end-page: 208
  ident: bib19
  article-title: Evidence for lysosomotropism of memantine in cultured human cells: cellular kinetics and effects of memantine on phospholipid content and composition, membrane fluidity and β – adrenergic transmission
  publication-title: Pharmacol Toxicol
– volume: 38
  start-page: 735
  year: 1999
  end-page: 767
  ident: bib29
  article-title: Memantine is a clinically well tolerated N-methyl-D-asparate (NMDA) receptor antagonist—a review of preclinical data
  publication-title: Neuropharmacology
– volume: 51
  start-page: 1
  year: 2005
  end-page: 17
  ident: bib30
  article-title: Dementia of Alzheimer's disease and other neurodegenerative disorders—memantine, a new hope
  publication-title: Pharmacol Res
– volume: 7
  start-page: 289
  year: 2013
  end-page: 296
  ident: bib14
  article-title: Quantitative targeted absolute proteomic analysis of transporters, receptors and junction proteins for validation of human cerebral microvascular endothelial cell line hCMEC/D3 as a human blood–brain barrier model
  publication-title: Mol Pharm
– volume: 29
  start-page: 227
  year: 2002
  end-page: 231
  ident: bib7
  article-title: PET studies of
  publication-title: Nucl Med Biol
– volume: 89
  start-page: 193
  year: 2003
  end-page: 208
  ident: bib26
  article-title: A review of blood-brain barrier transport techniques
  publication-title: Methods Mol Med
– volume: 16
  start-page: 29
  year: 2003
  end-page: 42
  ident: bib2
  article-title: Reduced glutamate neurotransmission in patients with Alzheimer's disease – an in vivo
  publication-title: MAGMA
– volume: 103
  start-page: 3335
  year: 2014
  end-page: 3341
  ident: bib17
  article-title: Transport characteristics of tramadol in the blood-brain barrier
  publication-title: J Pharm Sci
– volume: 102
  start-page: 3332
  year: 2013
  end-page: 3342
  ident: bib24
  article-title: Propranolol transport across the inner blood-retinal barrier: potential involvement of a novel organic cation transporter
  publication-title: J Pharm Sci
– volume: 54
  start-page: 342
  year: 1998
  end-page: 352
  ident: bib5
  article-title: Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine
  publication-title: Mol Pharmacol
– volume: 3
  start-page: RRN1291
  year: 2011
  ident: bib4
  article-title: Pharmacokinetics of memantine in rats and mice
  publication-title: PLos Curr
– volume: 19
  start-page: 1872
  year: 2005
  end-page: 1874
  ident: bib12
  article-title: Blood-brain barrier-specific properties of a human adult brain endothelial cell line
  publication-title: FASEB J
– volume: 29
  start-page: 1293
  year: 2009
  end-page: 1304
  ident: bib21
  article-title: Clonidine transport at the mouse blood–brain barrier by a new H
  publication-title: J Cereb Blood Flow Metab
– volume: 117
  start-page: 333
  year: 2011
  end-page: 345
  ident: bib11
  article-title: Quantitative targeted absolute proteomics of human blood–brain barrier transporters and receptors
  publication-title: J Neurochem
– volume: 62
  start-page: 173
  year: 2013
  end-page: 181
  ident: bib22
  article-title: Blood-to-brain influx transport of nicotine at the rat blood–brain barrier: involvement of a pyrilamine-sensitive organic cation transport process
  publication-title: Neurochem Int
– volume: 51
  start-page: 1
  year: 2005
  ident: 10.1016/j.dmpk.2014.12.006_bib30
  article-title: Dementia of Alzheimer's disease and other neurodegenerative disorders—memantine, a new hope
  publication-title: Pharmacol Res
  doi: 10.1016/j.phrs.2004.05.005
– volume: 30
  start-page: 847
  year: 2013
  ident: 10.1016/j.dmpk.2014.12.006_bib25
  article-title: Involvement of a novel organic cation transporter in verapamil transport across the inner blood-retinal barrier
  publication-title: Pharm Res
  doi: 10.1007/s11095-012-0926-y
– volume: 19
  start-page: 1872
  year: 2005
  ident: 10.1016/j.dmpk.2014.12.006_bib12
  article-title: Blood-brain barrier-specific properties of a human adult brain endothelial cell line
  publication-title: FASEB J
  doi: 10.1096/fj.04-3458fje
– volume: 117
  start-page: 333
  year: 2011
  ident: 10.1016/j.dmpk.2014.12.006_bib11
  article-title: Quantitative targeted absolute proteomics of human blood–brain barrier transporters and receptors
  publication-title: J Neurochem
  doi: 10.1111/j.1471-4159.2011.07208.x
– volume: 62
  start-page: 173
  year: 2013
  ident: 10.1016/j.dmpk.2014.12.006_bib22
  article-title: Blood-to-brain influx transport of nicotine at the rat blood–brain barrier: involvement of a pyrilamine-sensitive organic cation transport process
  publication-title: Neurochem Int
  doi: 10.1016/j.neuint.2012.11.014
– volume: 103
  start-page: 3335
  year: 2014
  ident: 10.1016/j.dmpk.2014.12.006_bib17
  article-title: Transport characteristics of tramadol in the blood-brain barrier
  publication-title: J Pharm Sci
  doi: 10.1002/jps.24129
– volume: 73
  start-page: 202
  year: 1993
  ident: 10.1016/j.dmpk.2014.12.006_bib19
  article-title: Evidence for lysosomotropism of memantine in cultured human cells: cellular kinetics and effects of memantine on phospholipid content and composition, membrane fluidity and β – adrenergic transmission
  publication-title: Pharmacol Toxicol
  doi: 10.1111/j.1600-0773.1993.tb01564.x
– volume: 2
  start-page: 1057
  year: 2010
  ident: 10.1016/j.dmpk.2014.12.006_bib13
  article-title: ABC and SLC transporter expression and proton oligopeptide transporter (POT) mediated permeation across the human blood–brain barrier cell line, hCMEC/D3
  publication-title: Mol Pharm
  doi: 10.1021/mp900178j
– volume: 36
  start-page: 2005
  year: 2008
  ident: 10.1016/j.dmpk.2014.12.006_bib9
  article-title: Involvement of the pyrilamine transporter, a putative organic cation transporter, in blood-brain barrier transport of oxycodone
  publication-title: Drug Metab Dispos
  doi: 10.1124/dmd.108.022087
– volume: 10
  start-page: 8
  year: 2013
  ident: 10.1016/j.dmpk.2014.12.006_bib16
  article-title: Functional expression of a proton-coupled organic cation (H+/OC) antiporter in human brain capillary endothelial cell line hCMEC/D3, a human blood–brain barrier model
  publication-title: Fluids Barriers CNS
  doi: 10.1186/2045-8118-10-8
– volume: 1778
  start-page: 42
  year: 2008
  ident: 10.1016/j.dmpk.2014.12.006_bib20
  article-title: Uptake of 3, 4-methylenedioxymethamphetamine and its related compounds by a proton-coupled transport system in Caco-2 cells
  publication-title: Biochim Biophys Acta
  doi: 10.1016/j.bbamem.2007.08.023
– volume: 206
  start-page: 297
  year: 1991
  ident: 10.1016/j.dmpk.2014.12.006_bib32
  article-title: Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study
  publication-title: Eur J Pharmacol
  doi: 10.1016/0922-4106(91)90113-V
– volume: 16
  start-page: 637
  year: 1999
  ident: 10.1016/j.dmpk.2014.12.006_bib31
  article-title: Brain penetration and in vivo recovery of NMDA receptor antagonists amantadine and memantine: a quantitative microdialysis study
  publication-title: Pharm Res
  doi: 10.1023/A:1018856020583
– volume: 34
  start-page: 1868
  year: 2006
  ident: 10.1016/j.dmpk.2014.12.006_bib18
  article-title: Molecular identification and functional characterization of rat multidrug and toxin extrusion type transporter 1 as an organic cation/H+ antiporter in the kidney
  publication-title: Drug Metab Dispos
  doi: 10.1124/dmd.106.010876
– volume: 10
  start-page: 4491
  year: 2013
  ident: 10.1016/j.dmpk.2014.12.006_bib8
  article-title: Memantine transport across the mouse blood–brain barrier is mediated by a cationic influx H+ antiporter
  publication-title: Mol Pharm
  doi: 10.1021/mp400316e
– volume: 29
  start-page: 1293
  year: 2009
  ident: 10.1016/j.dmpk.2014.12.006_bib21
  article-title: Clonidine transport at the mouse blood–brain barrier by a new H+ antiporter that interacts with addictive drugs
  publication-title: J Cereb Blood Flow Metab
  doi: 10.1038/jcbfm.2009.54
– volume: 10
  start-page: 1581
  year: 2013
  ident: 10.1016/j.dmpk.2014.12.006_bib27
  article-title: Confounding parameters in preclinical assessment of blood–brain barrier permeation: an overview with emphasis on species differences and effect of disease states
  publication-title: Mol Pharm
  doi: 10.1021/mp300570z
– volume: 119
  start-page: 324
  year: 2012
  ident: 10.1016/j.dmpk.2014.12.006_bib28
  article-title: Effect of renal impairment on the pharmacokinetics of memantine
  publication-title: J Pharm Sci
  doi: 10.1254/jphs.12043FP
– volume: 105
  start-page: 269
  year: 1998
  ident: 10.1016/j.dmpk.2014.12.006_bib1
  article-title: Neurotransmitter amino acids in cerebrospinal fluid of patients with Alzheimer's disease
  publication-title: J Neural Transm
  doi: 10.1007/s007020050073
– volume: 29
  start-page: 69
  year: 2014
  ident: 10.1016/j.dmpk.2014.12.006_bib15
  article-title: Functional expression of organic cation/carnitine transporter 2 (OCTN2/SLC22A5) in human brain capillary endothelial cell line hCMEC/D3, a human blood-brain barrier model
  publication-title: Drug Metab Pharmacokinet
  doi: 10.2133/dmpk.DMPK-13-RG-058
– volume: 42
  start-page: 443
  year: 2008
  ident: 10.1016/j.dmpk.2014.12.006_bib6
  article-title: Memantine-induced myoclonus and delirium exacerbated by trimethoprim
  publication-title: Ann Pharmacother
  doi: 10.1345/aph.1K619
– volume: 38
  start-page: 735
  year: 1999
  ident: 10.1016/j.dmpk.2014.12.006_bib29
  article-title: Memantine is a clinically well tolerated N-methyl-D-asparate (NMDA) receptor antagonist—a review of preclinical data
  publication-title: Neuropharmacology
  doi: 10.1016/S0028-3908(99)00019-2
– volume: 102
  start-page: 3332
  year: 2013
  ident: 10.1016/j.dmpk.2014.12.006_bib24
  article-title: Propranolol transport across the inner blood-retinal barrier: potential involvement of a novel organic cation transporter
  publication-title: J Pharm Sci
  doi: 10.1002/jps.23535
– volume: 29
  start-page: 227
  year: 2002
  ident: 10.1016/j.dmpk.2014.12.006_bib7
  article-title: PET studies of 18F-memantine in healthy volunteers
  publication-title: Nucl Med Biol
  doi: 10.1016/S0969-8051(01)00293-1
– volume: 100
  start-page: 3912
  year: 2011
  ident: 10.1016/j.dmpk.2014.12.006_bib10
  article-title: Diphenhydramine active uptake at the blood–brain barrier and its interaction with oxycodone in vitro and in vivo
  publication-title: J Pharm Sci
  doi: 10.1002/jps.22567
– volume: 16
  start-page: 29
  year: 2003
  ident: 10.1016/j.dmpk.2014.12.006_bib2
  article-title: Reduced glutamate neurotransmission in patients with Alzheimer's disease – an in vivo 13C magnetic resonance spectroscopy study
  publication-title: MAGMA
  doi: 10.1007/s10334-003-0004-x
– volume: 3
  start-page: RRN1291
  year: 2011
  ident: 10.1016/j.dmpk.2014.12.006_bib4
  article-title: Pharmacokinetics of memantine in rats and mice
  publication-title: PLos Curr
  doi: 10.1371/currents.RRN1291
– volume: 89
  start-page: 193
  year: 2003
  ident: 10.1016/j.dmpk.2014.12.006_bib26
  article-title: A review of blood-brain barrier transport techniques
  publication-title: Methods Mol Med
– volume: 7
  start-page: 289
  year: 2013
  ident: 10.1016/j.dmpk.2014.12.006_bib14
  article-title: Quantitative targeted absolute proteomic analysis of transporters, receptors and junction proteins for validation of human cerebral microvascular endothelial cell line hCMEC/D3 as a human blood–brain barrier model
  publication-title: Mol Pharm
  doi: 10.1021/mp3004308
– volume: 80
  start-page: 1564
  year: 2007
  ident: 10.1016/j.dmpk.2014.12.006_bib23
  article-title: Blood–brain barrier transport of pramipexole, a dopamine D2 agonist
  publication-title: Life Sci
  doi: 10.1016/j.lfs.2007.01.035
– volume: 54
  start-page: 342
  year: 1998
  ident: 10.1016/j.dmpk.2014.12.006_bib5
  article-title: Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine
  publication-title: Mol Pharmacol
  doi: 10.1124/mol.54.2.342
– volume: 18
  start-page: S23
  year: 2003
  ident: 10.1016/j.dmpk.2014.12.006_bib3
  article-title: The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence
  publication-title: Int J Geriatr Psychiatry
  doi: 10.1002/gps.938
SSID ssj0033542
Score 2.2405312
Snippet Memantine is clinically used for the treatment of patients with Alzheimer's disease and is highly distributed to the brain. The aim of this study is to...
SourceID proquest
pubmed
crossref
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 182
SubjectTerms Active transport
Biological Transport
Blood-Brain Barrier - cytology
Blood-Brain Barrier - drug effects
Blood-Brain Barrier - metabolism
Blood–brain barrier
Cell Line, Transformed
Endothelial Cells - drug effects
Endothelial Cells - metabolism
Feasibility Studies
hCMEC/D3 cells
Humans
Kinetics
Memantine
Memantine - metabolism
Membrane Transport Modulators - pharmacology
Models, Biological
Organic Cation Transport Proteins - antagonists & inhibitors
Organic Cation Transport Proteins - metabolism
Proton-coupled organic cation antiporter
RNA Interference
Transfection
Title Memantine transport by a proton-coupled organic cation antiporter in hCMEC/D3 cells, an in vitro human blood-brain barrier model
URI https://dx.doi.org/10.1016/j.dmpk.2014.12.006
https://www.ncbi.nlm.nih.gov/pubmed/25857234
https://www.proquest.com/docview/1672609815
Volume 30
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELba7YUL4s1SqAYJ9UKjTew43hyrpWUBbVWpRdqb5ae60CarbbbSHvkn_BZ-GZ44aYUEPXCMlZEtjz0Pa-b7CHmnHBXOMZWkPlchQVHhShXMJVQZ71PjlOfYKDw7KaZf889zPt8ik74XBssqO9sfbXprrbuRUbebo-ViMTrDJsicFYg4h8kV3yY7NHjXdEB2Dj99mZ70Bpkx3nLo4P8JCnS9M7HMy14tv2OFV96-CiLx0d_907_iz9YPHT8iD7sAEg7jGh-TLVc9IfunEYF6cwDndw1V1wewD6d32NSbp-THzF0pJIdw0PSw5qA3oAABG-oqMfV6eeksRLYnA_FFD1CmhUBfwaKCi8nsaDL6wACf_cMsqgqjv37eLJpVDS3rH8SCeI0EFKDVCnnxoGXdeUbOjo_OJ9OkY2FITF6mTcKscEYYwTKvSyc0V7Sw1pTah0iPU5v5VFOqS67YWHvkPcpUSHWtorlmjj0ng6qu3EsC1pcpT40IAarA97wxK3JfGMNsIZjRdEiyfuel6QDKkSfjUvaVaN8kakuitmRGZdDWkLy_lVlGeI57_-a9QuUfh0wG_3Gv3Nte-zLcPtxbVbl6fS2zQoSEsBxnfEhexGNxuw4aMjFBWf7qP2fdJQ_CF49lQq_JoFmt3ZsQATV6rzvhe2T74zz7DfaFB28
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZKe4AL4s3yHCTUC402seN4c6yWVlvaXVXqIvVm-SkW2mS1zSLtkX_Cb-GX4YmTVkjQA1cnI1ue8XjGmvk-Qt4rR4VzTCWpz1VIUFQ4UgVzCVXG-9Q45Tk2Ck9nxeRz_umcn2-Rcd8Lg2WVne-PPr311t3IsNvN4XKxGJ5hE2TOCkScw-SK3yE7iE4VzHxn_-h4MusdMmO85dDB_xMU6HpnYpmXvVx-wwqvvH0VROKjv99P_4o_23vo8AG53wWQsB_X-JBsueoR2T2NCNSbPZjfNFRd7cEunN5gU28ekx9Td6mQHMJB08Oag96AAgRsqKvE1OvlhbMQ2Z4MxBc9QJkWAn0Fiwq-jKcH4-FHBvjsH2ZRVRj99fP7olnV0LL-QSyI10hAAVqtkBcPWtadJ-Ts8GA-niQdC0Ni8jJtEmaFM8IIlnldOqG5ooW1ptQ-RHqc2synmlJdcsVG2iPvUaZCqmsVzTVz7CnZrurKPSdgfZny1IgQoAp8zxuxIveFMcwWghlNByTrd16aDqAceTIuZF-J9lWitiRqS2ZUBm0NyIdrmWWE57j1b94rVP5hZDLcH7fKveu1L8Ppw71VlavXVzIrREgIy1HGB-RZNIvrddCQiQnK8hf_Oetbcncyn57Ik6PZ8UtyL3zhsWToFdluVmv3OkRDjX7TWftvSecJbQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Memantine+transport+by+a+proton-coupled+organic+cation+antiporter+in+hCMEC%2FD3+cells%2C+an+in%C2%A0vitro+human+blood-brain+barrier+model&rft.jtitle=Drug+metabolism+and+pharmacokinetics&rft.au=Higuchi%2C+Kei&rft.au=Kitamura%2C+Atsushi&rft.au=Okura%2C+Takashi&rft.au=Deguchi%2C+Yoshiharu&rft.date=2015-04-01&rft.issn=1347-4367&rft.volume=30&rft.issue=2&rft.spage=182&rft.epage=187&rft_id=info:doi/10.1016%2Fj.dmpk.2014.12.006&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_dmpk_2014_12_006
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1347-4367&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1347-4367&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1347-4367&client=summon